Pipeline 2019-03-10T20:41:02+00:00
Our strategic focus is small molecule drugs that have proven history of safety, and have shown some efficacy in  clinical trials. We believe that our rescue and repositioning process can help relaunch these drugs as targeted therapies for solid tumors, addressing issues of drug resistance and tumor heterogeneity, either as mono therapy or in combination with other drugs.

Developed  by Indication Drugs R&D Preclinical Phase I Phase II Phase III

​Prostate​ and Ovarian Cancers


Lung​ Cancers



Prostate & Ovarian​ Cancer​


Mechanism of Action

LP-100 is a non-hormone, non-chemotherapy, DNA Damage Repair (DDR) inhibitor. It shows multiple cytotoxic effects on tumor cell biology such as DNA adduct formation, RNA polymerase stalling and redox protein modification.


LP-100 was first developed by MGI. Pharma and later in collaboration with global pharma company, Eisai.  After achieving an objective response rate in 12-15% of prostate and ovarian cancer patients in phase 2 and phase 3 clinical trials, the program was shelved. Irofulven has been in over 30 clinical trials with 900 patients treated and has a history of tolerability, safety and efficacy in certain tumor sub-types. Lantern process was to uncover a genomic signature that determines potential responders, develop suitable preclinical data, and successfully out-license it to Oncology Venture (a European Biotech) in 18 months.

Mechanism of Action

LP-300 is a first-in-class combination agent indicated in non-small cell lung cancer. With chemoprotective and chemosensitizing activity, LP-300 has potential as a  combination agent or adjuvant in front line, second line or salvage therapy in newly diagnosed, relapsed, metastatic or advanced NSCLC for overall survival enhancement and toxicity alleviation from primary chemotherapy or standard of care. LP-300 shows cysteine modifying activity on select proteins (ALK), and has shown that it modulates protein function (EGFR, MET, and ROS1). It also acts as a chemo-sensitizer for combination therapies by inactivating proteins that are modulating cellular redox status and drug resistance (TRX, GRX) and possesses chemoprotectant activity that reduces toxicities associated with Taxane / Platinum based chemotherapies. LP-300 has great promise to be used synergistically with various treatment regimens including chemotherapy, targeted therapy and immunotherapy combinations by virtue of its multi-modal mechanism of action, capacity to counter multi-drug resistance, and statistically significant survival outcomes in subgroups in previous clinical trials when combined with standard of care.

LP-300 has been in 4 major clinical trials with over 600 patients that were treated with demonstrable safety, and tolerability, but also with efficacy in certain patient populations. LP-300 in combination with Cisplatin and Paclitaxel demonstrated significant benefit in female non-smokers with advanced NSCLC adenocarcinoma. Although the phase 3 trial failed to achieve overall clinical efficacy, it did achieve (in retrospective analysis) overall survival (OS) of 25 months, with a 2-year survival rate of 51.4%, in females with advanced adenocarcinoma of the lung. These female cancer patients were uniformally receiving both paclitaxel/cisplatin and LP-300.
Mechanism of Action

LP-184 is a non-hormone, non-chemotherapy, next-generation DNA Damage Repair (DDR) inhibitor. Indicated primarily in solid tumors such as prostate and ovarian cancers along with renal, lung and brain cancers, LP-184 is a next generation analog of Irofulven. Developed through combinatorial chemistry and screened against conventional therapies both in vitro and in vivo with superior performance, LP-184 cytotoxicity is mediated through the Transcription Coupled Nucleotide Excision Repair (TC-NER) pathway, via alkylation of DNA leading to cell cycle arrest in S phase. Additional cytotoxic effects on tumor include generation of reactive oxygen species, chemical modification of various intracellular proteins, and induction of the MAPK pathway followed by apoptosis.


LP-184, demonstrates highly improved anti-tumor efficacy, tumor regression in a xenograft model of multidrug resistant cancer, therapeutic index, and bioavailability and clearance.